A join point regression analysis of trends in mortality due to osteoporosis in Spain by Dragomirescu, Ioana et al.
1Scientific RepoRts |          (2019) 9:4264  | https://doi.org/10.1038/s41598-019-40806-0
www.nature.com/scientificreports
A join point regression analysis 
of trends in mortality due to 
osteoporosis in spain
Ioana Dragomirescu1, Javier Llorca1,2,3, Inés Gómez-Acebo  1,2,3 & trinidad Dierssen-sotos1,2,3
osteoporosis is a major health problem in terms of fracture probability and disability. the aim of this 
ecological study is to identify the temporal trends in osteoporosis mortality in Spain from 1999 to 
2015. Data on the Spanish population and number of deaths due to osteoporosis were obtained from 
the Spanish National Institute for Statistics. Age-adjusted mortality rates were estimated. Join point 
regression was used to identify the years when changes in mortality s and annual percentage change in 
mortality rates took place. Women presented a greater mortality rate decrease (p < 0.001), though this 
mortality difference by sex was reduced by half at the end of the period. The higher the age, the faster 
the mortality rate declined in women, while no clear pattern could be identified in men. In women, 
significant changes in trends were identified in three age groups (50–54, 60–64 and 80–84 years old). 
A sustained decrease in osteoporosis-associated mortality was found in women aged 75–79 and ≥85 
years and men aged 60–64. In conclusion, mortality caused by osteoporosis in Spain is decreasing faster 
in the older age ranges especially in women.
Osteoporosis is defined as a systemic skeletal disease characterized by low bone mineral density (BMD) and 
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to 
osteoporotic fractures which are a leading cause of morbidity and mortality worldwide1,2. Due to its prevalence, 
osteoporosis is considered a serious public health concern. It is estimated that over 200 million people suffer 
from this disease worldwide3. It affects about 27.6 million people in the European Union, the prevalence being 
22.1% in women and 6.6% in men aged 50 years o over4. In Spain, the prevalence of osteoporosis is higher in 
women -reaching 26%- and lower in men -being 4.15%- and it is expected to increase with an aging population5. 
Men older than 50 present a 4.4% prevalence of hip osteoporosis and 4.8% of lumbar spine osteoporosis being 
much lower than in women5. In the USA, 2005–2008, the prevalence of osteoporosis of the lumbar spine ranges 
from 6.8% in women aged 50 to 596. The age group ≥75 years presents a considerable difference between hip 
and lumbar spine osteoporosis prevalence, being 24% and 40% respectively5. Osteoporotic fractures are widely 
considered to be the most serious outcome of osteoporosis and an increased risk of death is noticeably existent 
in both women and men, especially after hip fracture7. Regarding temporal trends of osteoporotic fracture reper-
cussions, studies in western populations have reported increases in hip fracture incidence through the second 
half of the 20th century; in the last two decades, however, rates seem to have stabilized while age-adjusted rates 
have decreased3. Azagra et al. have described that in Spain, the trend of hip fractures according to age groups 
and gender is clearly down, warding only women aged between 65 and 80 while this remains rather stable in the 
80–84-year-old group and presents a significant increase in the 85-year-old on groups. Nevertheless, the mortality 
rate dropped remarkably in both sexes8.
Changes in the osteoporotic fracture and mortality rates trend could be related to diagnosis and treatment 
improvements. Regarding the diagnosis, though Dual-energy X-ray absorptiometry (DXA) is the most widely 
used technique to assess bone mineral, there are others that include: quantitative ultrasound, quantitative com-
puted tomography, peripheral DXA, digital X-ray radiogrammetry, radiographic absorptiometry9 and magnetic 
resonance imaging10.
The WHO fracture prediction tool FRAX was created in 2008 in order to estimate fracture risk by using risk 
factors11. According to FRAX, a patient fracture risk over 10 years can be classified as low (<10% in the next 10 
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years), moderate (10–20% in the next 10 years), or high (>20% in the next 10 years)12. Other fracture risk calcu-
lators are available online13.
Regarding pharmacological interventions, for many years the prevention of postmenopausal bone loss was 
marked by the use of hormone replacement therapy (HRT)12 until in 2001, when Women’s Health Initiative study 
finding the association between HT and several cancers was published14,15. The widespread use in the prescrip-
tion of bisphosphonates in developed countries began in 2002. Since then, an increasing use has been observed16. 
Alendronate was the first oral bisphosphonate drug for treatment of osteoporosis in 1995, followed by risedronate 
in 1998, and ibandronate in 2005. The generic alendronate became available in 2008 and generic ibandronate in 
201212,17.
The effect that the introduction of new diagnosis methods and drugs for treating osteoporosis would have 
had on mortality due to osteoporosis is uncertain. The main objective of this study was to evaluate trends in the 
mortality rate of osteoporosis in Spain from 1999 until 2015 and their relationship to changes in diagnosis and 
treatment in recent decades.
Methods
Data extraction. This ecological study used data on the number of people dying from osteoporosis divided 
or grouped according to sex and within a 5-year-diffeence, age groups from 50 years old on were obtained from 
the Spanish National Institute for Statistics, which obtained its data from national death certificates that listed 
osteoporosis as the cause of death. Such deaths were identified implementing, ninth revision (ICD-9) diagnosis 
codes, M.80 through M81.9 according to the International Classification of Diseases.
statistical analysis. To identify changes in mortality rate trends, join point regression was estimated for 
every age and sex group by using the Join point Regression Program, Version 4.5.0.1 (Statistical Research and 
Applications Branch, National Cancer Institute).
In brief, by using mortality rates as inputs, this method identifies the year(s) when a trend change is produced, 
it calculates the annual percentage change (APC) in rates between trend-change points, and it also estimates the 
average annual percentage change (AAPC) in the whole period studied.
To estimate the APC, the following model is used:
Y b b xlog( )x 0 1= + , where log (Yx) is the natural logarithm of the rate in year x.
Then, the APC from year x to year x + 1 is:
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When there are no join points (i.e., no changes in trend), APC is constant, so it equals the AAPC. Otherwise, 
the whole period is segmented by the points with trend change. Then, AAPC is estimated as a weighted average of 
the estimated APC in each segment by using the segment lengths as weights. For instance, in 50- to 54-year-old 
men, join point regression identifies two join points in 2005 and 2009, so the whole period is segmented in three 
periods: 1999–2005, 2005–2009, and 2009–2015, with APC equal to – 0.014, − 0.032, and – 0.012, respectively, 
and segment widths equal to 6, 4 and 6 years, respectively. Then, AAPC is estimated as:
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2 is the estimate of the variance of bx obtained from the fit of the join point model.
The number of join points is obtained using a permutation test via Monte Carlo resampling18. Once the num-
ber k of join points has been obtained, the different models with k join points are compared by estimating their 
Bayesian Information Criterion (BIC)19. This procedure is detailed in the Supplementary material.
To further explore changes in trends related to events linked to diagnoses or treatment of osteoporosis in 
our country we have developed a point regression analysis not allowing the program to estimate the years of 
trend change, but pre-specifying the join points in 2003 (the year bisphosphonates were introduced) and 2008 
(the year generic bisphosphonates and FRAX were introduced). Therefore, this further analysis three set peri-
ods: (1) 1999–2003 release and implementation of the Guide of Diagnosis and Treatment of Osteoporosis, (2) 
2003–2008 the period of the bisphosphonates and (3) 2008–2015 the period of the generic bisphosphonates and 
FRAX introduction. APC for a pre-specified period is obtained as the average of the APCs previously obtained 
in the regular join point analysis, weighted by the number of years included in each period. This analysis has 
no meaning in age groups without join points: Firstly, let us further explain how it works when there is one join 
point: consider an age group with a join point in 2005, having APC = −1.5% in 1999–2005 and APC = −3.0% in 
2005–2015. In the analysis using pre-determined join points, we will have APC = −1.5% in 1999–2003 (as −1.5 
is the APC for the whole period 1999–2005), APC = [2*(−1.5%) + 10*(−3.0%)]/12, where 2 is the number of 
years with APC = −1.5 (i.e., 2003–2005) and 10 is the number of years with APC = −3.0% (i.e., 2005–2015). 
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Secondly, let us apply the same procedure when there is no join point: consider an age group without join points, 
having APC = −2.0% in 1999–2015. In the analysis with pre-determined points the result will always be the 
same: APC = −2.0% in 1999–2003, APC = −2.0% in 2003–2008 and APC = −2.0% in 2008–2015. The benefit of 
the analysis method used allow us to identify changes affecting different age groups in different years However, a 
more tradittional aproach (age- and sex-adjusted mortality rates) only would allow us to identify changes affect-
ing the population altogether. Moreover, changes in younger age groups could be undetectable -had they existed- 
as the impact of older age groups on age-adjusted mortality is much higher.
To further analyze mortality due to osteoporosis in Spain, an age, period and cohort analysis was performed 
using Poisson regression with natural cubic splines with six knots for age, five knots for period (=year of death) 
and three knots for birth cohort20.
Results
General trend in mortality. Figure 1 displays the decreasing trend of the age-adjusted mortality rates by 
gender, which is more pronounced in women (p < 0.001). During the period under study, the highest osteoporo-
sis mortality rate registered in Spain was in 1999, in both women and men (23.1/100.000 in women and 17.7/100 
000 in men), decreasing around 38% in women and 33% in men at the end of the period (2015). As women 
presented a higher rate decrease, mortality rate differences among women and men in 2015 –at the end of the 
period- halved those in 1999 (5.4/10000 in 1999 vs. 2.5/100000 in 2015).
Trend in mortality by age and sex according to the join points identified by the analysis. As 
osteoporosis is a disease influenced by age, in our analysis a specific analysis was made in age groups (five-year 
wide groups). Table 1 shows the trends in mortality caused by osteoporosis in Spain by gender, according to 
the join points identified by the analysis. Columns headed with AAPC indicate the trend in the whole period 
1999–2015: mortality due to osteoporosis decreased in most age groups in both women and men, although such 
a trend was more pronounced in women over 70. Columns headed with APC display the mortality trend in each 
period identified by the join point regression; in five age groups (namely, 55–59, 65–69, 70–74, 75–79 and 85+), 
the analysis found no join point in either men or women, so APC equals AAPC. Two join points were identified 
in the 50–54 years old group in 2005 and 2009, leading to three periods with different trend; the fastest descend-
ent trend in mortality was found in the intermediate period (2005/2009). Three periods (jointed in 2002 and 
2009) were also identified in women, but not in men, aged 60–64; the intermediate period (2002/2009) showed a 
3.4% annual decreased in mortality, while the trends were towards an increase in mortality in periods 1999/2002 
and 2009/2015 (2.9% and 0.4% annual increase, respectively). Two periods were identified in the 80–84-year-old 
group; in women, there was an almost plain trend in 1999/2004 and a strong decrease in 2004/2015 (−6.5% 
annual change), while in men the decrease began in 2007 (−13% decrease in 2007/2011), but it was followed by 
an increase in 2011/2015. Results from selected age groups are displayed in Fig. 2.
Trend in mortality defined by age and sex in pre-specified periods. To explore the influence of 
changes in treatment or diagnosis on mortality trends, we have estimated the average APC in three predefined 
periods (Table 2): the first one (1999–2003, before bisphosphonate introduction) presented only a 1.4% decrease 
both in women and men in the 50–54 years age group. Nevertheless, in the second period (2003–2008, after 
bisphosphonates introduction) the same age group presented a more pronounced decline in both genders com-
pared with the previous period (−2.5 95% CI −3.6 to −1.3 in women and −2.5% 95% CI −3.5 to −1.5 in men). 
In addition, women in the 80–84 years age group showed the higher significant decline (−5.2% (95% CI −6.4 to 
4.0)). Finally, between 2008–2015 (third period, after generic bisphosphonates and FRAX introduction) in the 
50–54 age group the decrease was 1.3% in women and 1.5% in men, the 6.5% decrease observed in women in the 
80–84 years age group is worth highlighting.
Of note, this analysis could only be carried out on those age groups which are in Table 1 and identified at least 
one join point (i.e.: at least two periods in mortality trend).
Figure 1. Age-adjusted mortality caused by Osteoporosis in Spain, 2000–2015; women (red line) and men 
(blue line).
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The age-period-cohort analysis did not find any period or cohort effect in neither women nor men. Its results 
are displayed in Supplementary Table 1 and Supplementary Fig. 1.
Discussion
According to our results, mortality rates by osteoporosis are decreasing in both Spanish women and men, the 
decline being faster in women aged over 70. Although we identified different trend periods in some age groups 
(namely, 50–54, 60–64, 80–84 years old), it is unclear whether the introduction of new diagnosis/screening tech-
niques such-as FRAX or DXA- or new drugs such-as bisphosphonates- could have played a role in the mortality 
trends we have described.
For a specific measure to be considered responsible for changes in mortality trend, one could have expected 
some age-related pattern emerging in the analysis. For instance, if alendronate had been generalized in women 
aged 70 onwards from, say, 2003, then a faster mortality decline could have been expected in women included in 
all age groups over 70. Our analysis, however, does not support the existence of any clear pattern, as only three 
non-consecutive age groups experienced trend changes, while most age groups had a sustained decrease in mor-
tality throughout the whole studied period. The fact that 11 out of 16 groups, organized or defined by age and sex 
have no join points strongly suggests that there has been no change in the study period.
Several factors would explain this lack of accelerated declining pattern after implementing new diagnosis/
treatments. Firstly, the low adherence to both osteoporotic treatment at the time of fracture occurrence and 
DXA testing21; secondly, a great variability observed in osteoporosis treatment among general practitioners, who 
prescribe medication to a high percentage of women without a high FRAX risk while keeping those women with 
a high FRAX risk untreated22. Lastly, in our analysis, we have not considered a lag period; i.e.: there could have 
been a delay between the introduction of new measures for reducing or treating osteoporosis and any effect of 
them on mortality.
Some results of ours are, however, noteworthy. The steepest decline observed was around 5% in specific age 
groups (75–79 years old women and 60–64 years old in men). Along the same lines, Azagra et al., studying hip 
fractures (the most serious cause of mortality) found that in women aged between 75–79 years, the incidence 
rate fell significantly by 7.7%8. In the same way, men in the 75–79 years old group presented a globally significant 
decrease that could be related to the recommendation of DXA in men from 70 years on23. Furthermore, screening 
rates were higher among men older than 75 years24.
In age groups where trend changes were identified, the largest decline in incidence rate was observed in 
women aged 80–84 years old in the 2004–2015 period. This trend is consistent with the decrease observed in 
osteoporosis diagnosis (from 73% to 69%) between 2002 and 201225. In this period, oral bisphosphonate initia-
tion shifted towards older women and those with prior fractures26, which corresponds to the increasing focus on 
primary and secondary fracture prevention of patients at elevated fracture risk given by WHO’s FRAX introduc-
tion. In addition, this age group is likely to represent patients with polypharmacy which is associated with better 
treatment adherence27. On the other hand, the lack of significant changes in tendency observed in men could 
be related to the fact that men were less likely to receive osteoporosis treatment (8%) compared with women 
(23.3%) after a hip fracture, as observed in a study between 2000 and 201028. Our results are consistent with 
a meta-analysis published by Bolland et al., which shows a 10% decrease of the mortality risk associated with 




Change year APC (95% CI) AAPC (95% CI) Change year APC (95%CI) AAPC (95% CI)
50–54 1999–2015 −1.7 (−2.3,−1.1) 1999–2015 −1.8 (−2.3, −1.3)
1999–2005 2005 − 1.4 (−2.1,−0.7) 1999–2005 2005 −1.4 (−2.1, −0.8)
2005–2009 2009 − 3.2 (−5.2,−1.1) 2005–2009 2009 − 3.2 (−5.0, −1.3)
2009–2015 − 1.0 (−1.8,−0.3) 2009–2015 − 1.2 (−1.8, −0.5)
55–59 1999–2015 None +1.2 (−3.5, +6.2) +1.2 (−3.5, +6.2) 1999–2015 None − 1.5 (−3.8, +1.0) −1.5 (−3.8, +1.0)
60–64 1999–2015 −0.8 (−1.3, −0.3) 1999–2015 None −5.1 (−8.9, −1.2) −5.1 (−8.9, −1.2)
1999–2002 2002 +2.9 (+0.6, +5.1)
2002–2009 2009 −3.4 (−4.1, −2.7)
2009–2015 +0.4 (−0.3, +1.2)
65–69 1999–2015 None −2.5 (−7.7, +3.1) −2.5 (−7.7, +3.1) 1999–2015 None +0.5 (−5.5, +6.9) +0.5 (−5.5, +6.9)
70–74 1999–2015 None −4.8 (−10.8, +1.6) −4.8 (−10.8, +1.6) 1999–2015 None −0.4 (−4.3, +3.6) −0.4 (−4.3, +3.6)
75–79 1999–2015 None −4.7 (−5.7, −3.7) −4.7 (−5.7, −3.7) 1999–2015 None −4.2 (−5.2, −3.1) −4.2 (−5.2, −3.1)
0–84 1999–2015 −4.4 (−5.9, −3.0) 1999–2015 −2.4 (−6.5, +1,8)
1999–2004 2004 +0.4 (−4.0, +5.0) 1999–2007 2007 +0.1 (−3.4, 3.6)
2004–2015 −6.5 (−7.9, −5.2) 2007–2011 2011 −13.0 (−25.7, +1.8)
2011–2015 +4.0 (−5.7, +14.7)
85+ 1999–2015 None −3.4 (−4.2, −2.7) 1999–2015 None −2.90 (−3.8, −2.0)
Table 1. Trends in mortality caused by Osteoporosis in Spanish women and men: Year of change of 
trend, annual percentage change, and annual average percentage change. APC = annual percent change; 
CI = confidence interval. AAPC = annual average percent change; CI = confidence interval.
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osteoporosis treatment in the older population29. However, an ecological studies developed in our country has 
failed to show correlation between the increasing use of antiresorptive therapy and the incidence of femoral 
fracture30.
On the other hand, in the youngest group (50–54 years) the greatest decrease in mortality was observed in the 
2005–2009 period, which could be related to the decline of the prescription of the HRT14,15 and the increasing use 
of bisphosphonates16. On the contrary, in the period 2009–2015 a slow decrease in th mortality rate was observed. 
We can specula that these changes in trend might be associated with the release of generic bisphosphonates14,31. 
Regarding this point, in February 2008 the brand alendronate patent expired and generic alendronate became 
available; four years later (2012) ibandronate was marketed as generic17. At the same time, practice guidelines in 
the UK and elsewhere recommended that generic alendronate should be viewed as the first-line treatment and 
this currently dominates many European markets32. Since the introduction of generic bisphosphonates, reports 
have consistently concluded that its adherence is poorer than the original brand32–34, which could eventually 
lead to higher rates of gastro-intestinal intolerance35, lower increase of lumbar spine and total hip bone mineral 
density36,37. In addition, age group 50–64 years present high level of treatment and low prevalence of risk fac-
tors38,39. In Spain, primary treatment has been associated with lower adherences than secondary treatment27. 
Treatment adherence represents a common problem in the treatment of osteoporosis34 and it is responsible for 
an increased risk of fracture of approximately 30%32 and increases the cost-effectiveness ratio of osteoporosis 
screening strategies26.
Finally, the different trends observed in groups organized by sex in the 60–64 year olds group must be stressed. 
In men, a sharp decline of mortality trends was detected through the whole period, while women showed a less 
pronounced decrease. This finding does not seem to be related to changes in bisphosphonates treatment, given 
that men were less likely to receive osteoporosis treatment after a hip fracture compared with women28. However, 
Figure 2. (A) Join point models 50–54 years. (B) Join point models 75–79 years. (C) Joinpoint models 80–84 
years. (D) Join point models +84 years.




AAPC (95% CI) AAPC (95% CI)
50–54
1999–2003 −1.4 (−2.1, −0.7) 1999–2003 −1.4 (−2.1, −0.8)
2003–2008 −2.5 (−3.6, −1.3) 2003–2008 −2.5 (−3.5, −1.5)
2008–2015 −1.3 (−1.9, −0.7) 2008–2015 −1.5 (−2.0, −0.9)
60–64
1999–2003 +1.2 (− 0.2, +2,7)
2003–2008 − 3.4 (− 4.1, −2.7)
2008–2015 − 0.1 (− 0.7, +0.4)
80–84
1999–2003 +0.4 (−4.0, +5.0) 1999–2003 +0.1 (−3.4, +3.6)
2003–2008 −5.2 (−6.4, −4.0) 2003–2008 −2.7 (−6.2, +0.9)
2008–2015 −6.5 (−7.9, −5.2) 2008–2015 −3.7 (−10.7, +3.9)
Table 2. Trends in mortality with pre-designed join point caused by Osteoporosis in Spanish men and women. 
AAPC = annual average percent change; CI = 95% confidence interval. *p < 0.05.
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the improvement of the evaluation and treatment of glucocorticoid-induced osteoporosis (the most common 
cause of secondary osteoporosis in men) could be related to this descendent trend40,41. On the other hand, two 
significant join points were detected in women between 60–64 years old, showing opposite trends: an increase 
of mortality rate at the early years (1999–2002) and a markedly subsequent decline (2002–2009). The initial 
increase was probably related to the fact that hormone therapy was the most commonly prescribed treatment 
in postmenopausal women before 200112, while the later decline could probably be due to the introduction of 
bisphosphonates from 2002 despite the decline of the proportion of women under 65 years old meeting treatment 
criteria applying FRAX since 200811.
In addition to the new diagnostic methods and treatments, some articles in the United States42, Canadá43, 
Sweden44, Denmark45, Portugal46 and Korea, suggest that trends in mortality from osteoporosis could be moti-
vated by a birth cohort effect. For example, the economic or political situation of a country that leads to better or 
worse maternal nutrition and the nutrition of children47. However, few articles have evaluated cohort and period 
effects and their results are contradictory regarding the period effect43,44,48–50. However, recent studies suggest that 
the birth cohort effect and the period effect suppose a significant reduction in the incidence of hip fracture in each 
cohort or subsequent birth period and these effects are more marked among women than among men43,44. In our 
article, we have found no birth cohort effect on death due to osteoporosis.
Some reproductive factors observed in United States such as the increase in the average number of repro-
ductive years51, are not sustained either, given that they do not explain the parallel changes in the decrease in 
hip fractures in men. Similarly, other authors consider other factors such as an increase in calcium and vitamin 
D intake52, a higher BMI53, greater physical activity, smoking cessation51 and the prevention of falls54 to explain 
the decreasing trends in the incidence of hip fracture. It may contribute to the decline of hip fractures and there-
fore the decline of mortality due to osteoporosis. New investigations are necessary to prove it. Despite the high 
prevalence of osteoporosis in older population, its impact on mortality has scarcely been studied. To the best of 
our knowledge, this is the first study evaluating trends on mortality caused by osteoporosis developed in Spain. 
However, our study also has some limitations. Firstly, Join point regression consists in an ecological study, so 
causal relationship cannot be established and our results require further confirmation with individual-level data. 
As such, we can only hypothesize about associations highlighted by our data and have strayed from making 
claims of causality. Secondly, databases of the Spanish National Institute of Statistics do not provide osteoporosis 
classification data so we are not able to determine which data corresponds to primary osteoporosis or second-
ary one. Thirdly, the scarce number of studies focused on osteoporosis mortality makes it difficult to compare 
our results and forces us to contrast them with studies focused on osteoporotic fractures. However, we consider 
osteoporotic fractures an acceptable proxy to mortality because it has been demonstrated that general fractures, 
and especially hip fractures, are related to reducing personal autonomy through disability and dependence55, 
influencing the quality of life56,57 and even mortality58,59.
In conclusion, osteoporosis mortality in Spain is decreasing faster in the older age cohorts especially in 
women; the causes of this are not clear, but it cannot be fully attributed to improvements in osteoporosis diagno-
sis or screening or in primary or secondary osteoporosis prevention via bisphosphonates. Further observational 
studies with individual-level data are needed to clarify if new diagnosis, preventative tools, or their combination 
could contribute to these changes on mortality due to osteoporosis.
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